Overview

A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This was a multicenter, randomized, double-blind, parallel-group, three-arm, placebo-controlled study designed to demonstrate the efficacy of two different formulations of omalizumab compared with placebo in reducing the airway reaction to an inhaled aeroallergen solution in adult subjects with mild allergic asthma.
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Antibodies, Monoclonal
Omalizumab